Elicera Therapeutics AB (OSTO:ELIC) FCF Yield %: -15.90 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ELIC Elicera Therapeutics AB OSTO:ELIC
25 GF Score
Price kr2.62
! 1 Warning Sign
View Full Analysis

What is Elicera Therapeutics AB FCF Yield %?

Elicera Therapeutics AB OSTO:ELIC -1.50% 25 FCF Yield % is -15.90 as of Jul. 16, 2026. GuruFocus rates OSTO:ELIC with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, Elicera Therapeutics AB ranks worse than 62.1% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Elicera Therapeutics AB's Trailing 12-Month Free Cash Flow is kr-27.79 Mil, and Market Cap is kr174.85 Mil. Therefore, Elicera Therapeutics AB's FCF Yield % for today is -15.90%.

The historical rank and industry rank for Elicera Therapeutics AB's FCF Yield % or its related term are showing as below:

OSTO:ELIC' s FCF Yield % Range Over the Past 10 Years
Min: -15.9   Med: 0   Max: 0
Current: -15.9

OSTO:ELIC's FCF Yield % is ranked worse than
62.1% of 1409 companies
in the Biotechnology industry
Industry Median: -9.47 vs OSTO:ELIC: -15.90

Elicera Therapeutics AB's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

Elicera Therapeutics AB FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Elicera Therapeutics AB FCF Yield % Related Terms

Elicera Therapeutics AB FCF Yield % Historical Data

* Premium members only.

The historical data trend for Elicera Therapeutics AB's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicera Therapeutics AB FCF Yield % Chart

Elicera Therapeutics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial -14.39 -12.33 -16.54 -40.04 -8.51

Elicera Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.19 -8.24 -6.07 -15.91 -10.84

OSTO:ELIC vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, Elicera Therapeutics AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicera Therapeutics AB FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's FCF Yield % falls into.


OSTO:ELIC
25GF Score
Elicera Therapeutics AB OSTO:ELIC
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicera Therapeutics AB FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Elicera Therapeutics AB's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-21.551 / 253.356539389
=-8.51%

Elicera Therapeutics AB's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-6.982 * 4 / 257.724790798
=-10.84%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -15.90 mean?
Elicera Therapeutics AB (OSTO:ELIC) has a FCF Yield % of -15.90 as of Jul. 16, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Elicera Therapeutics AB and its competitors. According to the industry distribution chart, Elicera Therapeutics AB ranks #875 out of 1409 companies in the Biotechnology industry, placing it in the top 62.1%.
Is Elicera Therapeutics AB's FCF Yield % too high?
Elicera Therapeutics AB's current FCF Yield % is -15.90. Based on the distribution chart, Elicera Therapeutics AB ranks #875 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Elicera Therapeutics AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Elicera Therapeutics AB's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Elicera Therapeutics AB ranks #875 out of 1409 companies for FCF Yield %. This places Elicera Therapeutics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Elicera Therapeutics AB and its competitors. Elicera Therapeutics AB's current FCF Yield % is -15.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicera Therapeutics AB stock overvalued right now?
Elicera Therapeutics AB (OSTO:ELIC) has a current FCF Yield % of -15.90. The current FCF Yield % is -15.90. Elicera Therapeutics AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Elicera Therapeutics AB (OSTO:ELIC), the current FCF Yield % is -15.90 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicera Therapeutics AB Business Description

Other Exchanges 8E8:Germany
Address Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, 412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
25GF Score

Get the complete analysis for OSTO:ELIC

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.62
Price